Medical Oncologist
CION Cancer Clinics
CHEK2 mutation: which cancers, and how much risk | CION Cancer Clinics
A CHEK2 fault mainly raises the risk of breast cancer, and it raises it moderately rather than steeply. Links to prostate, bowel, kidney and thyroid cancer are weaker and less certain. This page explains which cancers are involved, how strong each link is, how CHEK2 compares with BRCA, and how your own risk is worked out from your variant and family history. At CION Cancer Clinics, our oncologists explain what a gene result means for you and your family, and plan the checks that follow.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Which cancers does a CHEK2 fault raise the risk of?
- How strong is the link for each cancer?
- How is a CHEK2 carrier's own risk estimated?
- What do the risk words on a CHEK2 report mean?
- How does CHEK2 compare with BRCA?
- What this page cannot tell you
- Four things people assume about CHEK2 risk
- Common questions about CHEK2 cancer risk
The short answer
Which cancers does a CHEK2 fault raise the risk of?
Mainly breast cancer. A CHEK2 fault raises breast cancer risk moderately, roughly two to three times the average in large studies. The links to prostate, bowel, kidney and thyroid cancer are weaker, and for some of these the evidence is still unsettled.
Moderate, not high
CHEK2 is called a moderate-risk gene. That puts it below BRCA1 and BRCA2, where the rise in breast and ovarian risk is much steeper. It matters, because the plan for a CHEK2 carrier is usually lighter. Extra breast screening is common. Preventive surgery is discussed far less often.
Your family history changes the picture
Two women with the same CHEK2 fault can have quite different risks. A carrier whose mother and sister both had breast cancer at a young age sits higher than a carrier with no affected relatives. The exact variant matters too. Doctors now fold the fault and the family tree together to estimate one personal figure.
What moderate means in everyday terms
Most women will never develop breast cancer. For a CHEK2 carrier the chance is higher, but most carriers still do not develop it. The point of knowing is to find any cancer early, when treatment is simpler, and to plan screening around real risk rather than fear.
A CHEK2 fault raises risk. It does not mean cancer will happen.Cancer by cancer
How strong is the link for each cancer?
The evidence is not equally strong for every cancer. Here is where it stands today, from clearest to least certain.
Breast cancer in women
The clearest link. Risk is moderately raised, and the cancers that do develop are more often hormone-sensitive, meaning they use oestrogen to grow. This is the risk that drives screening advice for female carriers, and it is the one most studies agree on.
A second breast cancer
A woman who has already had breast cancer and carries CHEK2 has a higher chance of a new cancer in the other breast than other survivors. This is a new cancer, not a return of the first. It is one reason follow-up after treatment may include yearly imaging of both breasts.
Cancers in men
Male breast cancer and prostate cancer both appear somewhat more often in carriers. The rise is modest, but it is enough for many doctors to discuss prostate checks with male carriers. A lump behind the nipple in a man should always be checked.
Bowel, kidney and thyroid
Some studies show a small rise, others do not. Screening for these is usually based on your family history rather than on the CHEK2 result alone.
Not clearly raised
- Ovarian cancer
- Most other cancers
Not sure whether this applies to you?
Ask an oncologistWorking out your figure
How is a CHEK2 carrier's own risk estimated?
The exact variant
A change that cuts the gene short behaves differently from a single-letter change. The second type often carries a lower risk.
The family tree
Who had cancer, which cancer and at what age, on both sides. This is often the biggest single factor after the variant itself.
Your own history
Age, previous breast biopsies, breast density on a mammogram, and when periods started and stopped all adjust the figure up or down. Pregnancies and breastfeeding count too.
A risk model
Your counsellor feeds all of this into a validated risk tool. The result guides whether you need extra screening, and from when. It can be updated if a relative is diagnosed later.
On your report
What do the risk words on a CHEK2 report mean?
- Moderate penetrance
- Penetrance means how often a fault leads to cancer. Moderate means clearly raised, but well below BRCA1 or BRCA2.
- Lifetime risk
- The chance of developing a cancer at any point up to old age. It is not the chance of it happening this year.
- Relative risk
- How many times higher your risk is than average. It says nothing on its own about how common the cancer is.
- Truncating variant
- A change that cuts the gene's instruction short, so the protein cannot work at all.
- Missense variant
- A single-letter change that alters the protein slightly. Some CHEK2 missense changes carry only a small risk.
- Hormone receptor-positive
- A breast cancer that uses oestrogen to grow. It is the more common type in CHEK2 carriers.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Side by side
How does CHEK2 compare with BRCA?
CHEK2
BRCA1 or BRCA2
Moderately raised breast cancer risk
Much higher breast cancer risk
Ovarian risk not clearly raised
Ovarian risk clearly raised
Extra breast screening is the usual plan
Screening, and preventive surgery is often discussed
Family history weighs heavily on the figure
The gene itself drives most of the risk
Being straight with you
What this page cannot tell you
It cannot give you your own risk figure. That depends on your exact variant, your family tree and your own history, worked through a risk model. What your specific variant means is a question for the counsellor who ordered the test.
It cannot settle the weaker links
Most CHEK2 research comes from European families, and studies in Indian families are still small. The common European variant is rare here. Figures for bowel, kidney and thyroid cancer may change as more data arrives, and your counsellor will tell you what is current.
Who this does not apply to
If your report lists a CHEK2 variant of uncertain significance, it is not a positive result, and none of these risks should be applied to you. If a CHEK2 change was found only in a tumour sample, that is a somatic change covered on our targeted therapy pages. Most people reading this do not carry a CHEK2 fault at all.
Men carry and pass on CHEK2 just as women do. Leave them out of the family tree and the picture is incomplete.Commonly believed
Four things people assume about CHEK2 risk
"CHEK2 is just as serious as BRCA."
It raises breast cancer risk less steeply, and it does not clearly raise ovarian cancer risk. The plan is usually lighter as a result.
"CHEK2 means I should have my ovaries removed."
Current guidance does not recommend it on the CHEK2 result alone, because ovarian risk is not clearly raised. A strong family history of ovarian cancer is a separate conversation.
"Every CHEK2 variant carries the same risk."
They do not. Some single-letter changes carry a much smaller risk than changes that cut the gene short.
"Men do not need to know about CHEK2."
Men can pass it to daughters and sons, and their own risk of prostate and male breast cancer is modestly raised.
Questions we are asked
Common questions about CHEK2 cancer risk
Will I definitely get breast cancer with a CHEK2 fault?
No. Most CHEK2 carriers never develop breast cancer. The fault raises your risk above average, which is why extra screening is often offered. How much it is raised for you depends on your variant and family history.
Does CHEK2 raise ovarian cancer risk?
Current evidence does not show a clear rise, and guidelines do not recommend preventive removal of the ovaries on a CHEK2 result alone. If ovarian cancer runs in your family, your counsellor will look at that separately.
I have had breast cancer. Does CHEK2 change anything now?
It can shape follow-up, because the chance of a new cancer in the other breast is higher. Your oncologist will discuss whether closer screening of the other breast makes sense. It does not usually change the treatment already under way.
Should male carriers be screened for prostate cancer?
Many doctors discuss it, because the risk is modestly raised. Whether and when to start is a shared decision with your doctor, weighing your family history against the downsides of testing.
Do I need colonoscopies because of CHEK2?
Not always. The link to bowel cancer is weak, so bowel screening is usually planned on your family history. If close relatives had bowel cancer, earlier colonoscopy may be recommended for that reason.
Is CHEK2 common in India?
It is found on Indian breast cancer panels, but the best-known European variant is rare here. Indian data on how common CHEK2 faults are, and on their exact risks, is still limited.
How do I find out my own risk figure?
See a genetic counsellor with your report and a family tree covering both sides. They will use a risk model that combines your variant, relatives and personal history into one estimate, and explain what it means for screening.
Can my children inherit CHEK2 from me?
Each child has a one in two chance of inheriting the fault, whether you are a man or a woman. Testing usually waits until they are adults, because the risk belongs to adult life.
Your Specialists
Meet CION's oncologists. Bring your family history or genetic report to them.
Our medical oncologists see people with a strong family history of cancer, arrange genetic counselling and testing where it fits, and plan the checks that follow.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- MedlinePlus Genetics — CHEK2 gene
- National Cancer Institute — Genetics of Breast and Gynecologic Cancers (PDQ)–Health Professional Version
- NCCN — Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate
- National Cancer Institute — Genetic Testing for Inherited Cancer Susceptibility Syndromes
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Low-penetrance variants and why they confuse peopleWhy some CHEK2 changes carry much less riskSurveillance for CHEK2 carriersWhat screening the risk actually calls forThe CHEK2 1100delC variantThe best-studied CHEK2 change, and what it tells usThe CHEK2 gene: what it doesWhat the gene does in a healthy cell
Talk to us
Want your own CHEK2 risk worked out properly?
Bring your report and what you know of your family history. A genetic counsellor can estimate your personal risk and explain what screening it calls for. One helpline serves every CION centre.